Cartesian Therapeutics to Present Late-Breaking Data from Phase 1/2a Trial of RNA CAR T-cell Therapy in Patients with Generalized Myasthenia Gravis
– Data Presentation Today at 14th Myasthenia Gravis Foundation of America International Conference on Myasthenia and Related Disorders in Miami – GAITHERSBURG, Md., May 10, 2022 – Cartesian Therapeutics, a fully integrated clinical-stage biotechnology company pioneering RNA cell therapy in and beyond oncology, will present late-breaking interim data from its Phase 1/2a clinical trial of Descartes-08 in patients […]